瑞波西汀与多虑平治疗老年抑郁症对照研究

目的观察瑞波西汀治疗老年抑郁症的疗效和安全性。方法随机将60例年龄≥60岁的老年抑郁症患者分为多虑平组（30例）和瑞波西汀组（30例），疗程6周，采用汉密尔顿抑郁量表（HAMD）和副反应量表（TESS）在治疗前和治疗后1、2、4、6周末评定药物疗效和副反应。结果两组疗效无显著差异，HAMD总分反各因子分从疗后2周至6周均较治疗前显著降低，两组间比较无显著性差异；治疗结束时TESS评分瑞波西汀组显著低于多虑平组。结论瑞波西汀适合于老年抑郁症患者的治疗，服用方便、安全，可首选使用。

A comparative study of reboxetine and doxepine in the treatment of patients with depression in old age

Objective To study the efficacy and safety of reboxetine in the treatment of patients with depression in old age.Methods A total of 60 elderly patients with depression were randomly divided into reboxetine group(n=30) and doxepine(n=30) group for the treatment of 6 weeks.HAMD and TESS were used to assess the efficacy and side effects before and on the 1st,2~ nd ,4~ th and 6~ th weekend after the treatment.Results There was no significant difference in efficacy between the two groups.Total score and the factor-scores of HAMD in two groups were markedly decreased after treatment.No significant differences were observed between the two groups.Total score of TESS in reboxetine group was significantly lower than that of doxepine group.Conclu-sion Reboxetine is effective and safe for elderly patients with depression.